AIIMS launches advanced therapeutic drug monitoring facility for epilepsy patients

The Neurobiochemistry Laboratory at AIIMS Delhi has launched a new Therapeutic Drug Monitoring facility to improve epilepsy care. The service aims to provide affordable testing for patients across India. Officials said it will help optimise treatment and reduce reliance on costly private labs.

The All India Institute of Medical Sciences in Delhi announced the launch on Sunday. The facility is housed in the Neurobiochemistry Laboratory at the Neurosciences Centre. It specialises in measuring medication concentrations in patients to support antiepileptic therapy.

The service enables accurate monitoring of drug levels, individualised dose adjustments, assessment of treatment response and early detection of toxicity. Hospital officials stated that the in-house tests will benefit economically underprivileged patients.

Previously many patients had to use expensive private laboratories or external referral centres for such specialised investigations. The new facility is expected to improve access to high-quality neurodiagnostic services nationwide.

Artigos relacionados

Isomorphic Labs, a spinoff of Google DeepMind, announced that its AI-designed drugs are progressing to human trials. President Max Jaderberg shared the news at WIRED Health in London, highlighting a “broad and exciting pipeline of new medicines.” The development builds on DeepMind’s AlphaFold platform.

Reportado por IA

A Chinese research team has developed an AI platform called GalaxyVS that screens potential drugs in seconds.

Sankara Nethralaya inaugurated an Experience Centre for People with Low Vision on Wednesday in collaboration with Enablemart. The centre provides assistive technologies and support services during Global Accessibility Awareness Day 2026 celebrations.

Este site usa cookies

Usamos cookies para análise para melhorar nosso site. Leia nossa política de privacidade para mais informações.
Recusar